Avadel Pharmaceuticals plc each representing one Ordinary Share (AVDL): Price and Financial Metrics
GET POWR RATINGS... FREE!
AVDL POWR Grades
- Sentiment is the dimension where AVDL ranks best; there it ranks ahead of 61.84% of US stocks.
- AVDL's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- AVDL ranks lowest in Growth; there it ranks in the 4th percentile.
AVDL Stock Summary
- Of note is the ratio of Avadel Pharmaceuticals Plc's sales and general administrative expense to its total operating expenses; 99.91% of US stocks have a lower such ratio.
- The ratio of debt to operating expenses for Avadel Pharmaceuticals Plc is higher than it is for about 95.69% of US stocks.
- Revenue growth over the past 12 months for Avadel Pharmaceuticals Plc comes in at -81.66%, a number that bests just 2.15% of the US stocks we're tracking.
- Stocks that are quantitatively similar to AVDL, based on their financial statements, market capitalization, and price volatility, are VET, REPH, NOA, TGB, and HBM.
- Visit AVDL's SEC page to see the company's official filings. To visit the company's web site, go to www.avadel.com.
AVDL Stock Price Chart Interactive Chart >
AVDL Price/Volume Stats
| Current price | $7.85 | 52-week high | $10.32 |
| Prev. close | $7.85 | 52-week low | $4.83 |
| Day low | $7.60 | Volume | 934,100 |
| Day high | $7.86 | Avg. volume | 401,555 |
| 50-day MA | $7.97 | Dividend yield | N/A |
| 200-day MA | $7.25 | Market Cap | 459.13M |
Avadel Pharmaceuticals plc each representing one Ordinary Share (AVDL) Company Bio
Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products based on its proprietary drug delivery technology for primary care and sterile injectable markets in the United States, France, and Ireland. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. The company was founded in 1990 and is based in Dublin, Ireland.
Latest AVDL News From Around the Web
Below are the latest news stories about Avadel Pharmaceuticals Plc that investors may wish to consider to help them evaluate AVDL as an investment opportunity.
Avadel Presents New Clinical Data from Pivotal Phase 3 REST-ON Trial Supporting Clinical Benefit of FT218 in Patients with Narcolepsy at SLEEP 2021Data show improvement in excessive daytime sleepiness for both narcolepsy subtypes and with and without stimulant use; demonstrate decreases in weight and body mass indexPost hoc analyses further support positive primary and secondary endpoint data for all evaluated doses of FT218Company hosting virtual medical booth to provide detailed information about ongoing research and publications DUBLIN, Ireland, June 09, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focus |
Avadel to Present New Efficacy and Safety Data from Pivotal Phase 3 REST-ON Trial of FT218 at SLEEP 2021DUBLIN, Ireland, June 03, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announced it will present primary and secondary endpoint data, including new post hoc analyses, from the pivotal Phase 3 REST-ON clinical trial at SLEEP 2021, at the 35th Annual Meeting of the Associated Professiona |
Avadel Pharmaceuticals Expands Leadership Team with Three Strategic HiresBolsters team with addition of established biopharma industry leaders in advance of anticipated regulatory approval and commercialization of once-nightly FT218 for narcolepsyDUBLIN, Ireland, June 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today it has appointed Jeff Cruikshan |
Avadel Pharmaceuticals to Present at the Jefferies Virtual Healthcare ConferenceDUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat on Tuesday, June 1 at 9:00 a.m. ET. A live webcast of this event, as well as an archived recording, will be available on Avadel’s Investor Relations website, www.investors.avadel.com, for 90 days following the conference. About Avadel Pharmaceuticals plcAvadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once... |
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the... |
AVDL Price Returns
| 1-mo | -3.21% |
| 3-mo | -14.21% |
| 6-mo | 13.28% |
| 1-year | -17.02% |
| 3-year | 4.11% |
| 5-year | -17.37% |
| YTD | 17.51% |
| 2020 | -11.52% |
| 2019 | 192.64% |
| 2018 | -68.54% |
| 2017 | -21.08% |
| 2016 | -14.91% |
Continue Researching AVDL
Want to see what other sources are saying about Avadel Pharmaceuticals Plc's financials and stock price? Try the links below:Avadel Pharmaceuticals Plc (AVDL) Stock Price | Nasdaq
Avadel Pharmaceuticals Plc (AVDL) Stock Quote, History and News - Yahoo Finance
Avadel Pharmaceuticals Plc (AVDL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...